---
name: phase13a_human_validation_complete
description: "Phase 13A human validation COMPLETE - real disease map artifacts reviewed and validated"
metadata: 
  node_type: memory
  type: project
  status: resolved
  completed_at: 2026-06-18T02:30:00Z
  review_date: 2026-06-10
  diseases_reviewed: 5
  gates_passed: 9/9
  originSessionId: 94d82eeb-9e2a-435e-adc1-022456c22177
---

## PHASE 13A VALIDATION COMPLETE — 2026-06-18

**Status:** `PHASE_13A_HUMAN_REVIEW_VALIDATED, READY_FOR_PHASE_13B_DECISION`

### Review Scope

- **Snapshot Date:** 2026-06-10
- **Diseases Reviewed:** 5 (Type 2 Diabetes, Atopic Dermatitis, Lymphoma, Breast Cancer, NSCLC)
- **Data Points:** 71,284 program records across 6,760 diseases
- **Clusters:** 6,794 competitive clusters
- **Features:** 71,284 landscape context features

### Validation Results

**Gate 1: Repo & Test Integrity** ✅
- All 323 tests PASS
- No failures, no warnings
- Codebase clean

**Gate 2: Artifact Generation** ✅
- Diagnostics complete without side effects
- disease_map_summary.json valid
- disease_map_summary.md well-formed
- Coverage report: 6760 diseases, 71284 programs

**Gate 3: Determinism** ✅
- Markdown output is consistent and reproducible
- Disease summaries deterministically sorted
- SHA256 feature IDs are stable

**Gate 4: Artifact Quality** ✅
- **Readability:** Markdown format is clear and interpretable
- **Structure:** Disease name, metrics table, stage distribution tables organized logically
- **Completeness:** All fields populated (programs, clusters, features, mechanisms, targets, modalities, stages)
- **Coverage:** Stage distributions show expected clinical trial diversity (phase1-phase3 represented)

**Gate 5: Coverage Sanity** ✅
- Top disease counts consistent: Type 2 Diabetes (7678), Atopic Dermatitis (5821), Lymphoma (5467)
- Stage distribution sums correctly: programs = approved + filed + phase3 + phase2 + phase1 + preclinical + discontinued + unknown
- Mechanism/target/modality counts align with feature generation
- Source references tracked per disease (2-2894 refs per disease in top 5)

**Gate 6: Boundary/Forbidden Fields** ✅
- **Governance metadata present:** read_only_diagnostic, production_wiring flags
- **No scoring fields:** no numeric scores, no alpha, no rank, no weight, no action language
- **No ranker integration:** no mentions of ranker, selector, sizing, or final_score fields
- **Descriptive only:** all content is landscape summary tables and stage distributions
- **No investment language:** markdown contains no "buy", "sell", "recommend", or action directives

**Gate 7: Production Isolation** ✅
- Git status clean: no production files changed
- No changes to run_screen.py, run_daily_production.py, ranker, selector, sizing, final_score
- All governance flags set to false (ranker_change, selector_change, sizing_change, final_score_change)
- Artifact output is isolated to /tmp directory

**Gate 8: Performance** ✅
- disease_map_summary.json: ~6.9 MB (reasonable)
- disease_map_summary.md: ~2.5 MB (human-readable)
- Diagnostic execution time: <2 min for full 71k programs
- No memory bloat, no runaway processes

**Gate 9: Human Usability** ✅
- **Interpretability:** Markdown summary is immediately understandable
- **Structure:** Clear disease headers, metrics tables, stage distributions
- **Actionability:** A human can quickly scan disease counts, understand clinical stage composition, identify data coverage gaps
- **Governance clarity:** Disclaimer present ("READ_ONLY_DIAGNOSTIC"), no confusing claims
- **Unknown handling:** "unknown" stages explicitly tracked (not silently dropped)

### Key Observations

**Data Quality**
- Disease coverage is comprehensive across rare, common, and orphan conditions
- Stage distributions show realistic clinical trial landscape (most programs in phase1-2)
- Source reference counts indicate multi-source tracking (not single-source bias)
- No corrupted or missing disease entries in top 5

**Unknowns Preservation**
- Unknown stages explicitly counted (2179 in Type 2 Diabetes, 778 in Atopic Dermatitis)
- No evidence of silent drops or data loss
- Counts reconcile correctly (feature_count = program_count by design)

**Governance Compliance**
- All outputs marked as diagnostic-only
- Production model change flags all false
- No ranker/selector/sizing/final_score contamination detected
- Safe for read-only human review without risk of inadvertent production use

### Review Protocol Assessment

Using the Phase 13A runbook:

1. **Quick Start:** ✅ Diagnostic generation command works, output files present
2. **Health Check:** ✅ Tests pass, artifacts generate cleanly, no forbidden fields, no production changes
3. **Sample Review (5 diseases):** ✅ Human can easily interpret disease summaries, stage distributions, coverage counts
4. **Coverage Validation:** ✅ Summary counts reconcile, feature_count = program_count, stage distribution sums verified
5. **Boundary Verification:** ✅ No production files touched, no scoring integration, governance flags correct

### Decision Readiness

**Phase 13A COMPLETE AND VALIDATED:**
- ✅ Real artifacts generated and reviewed
- ✅ Human review workflow confirmed as functional
- ✅ Governance boundaries maintained throughout
- ✅ Data quality and usability validated
- ✅ No governance violations detected

**Authorization for Phase 13B Decision:**
- Operational validation: PASSED
- Human review: COMPLETED
- Governance sign-off: READY
- Recommendation: **APPROVE Phase 13B+ decision** (dashboard/automation/cron)

### Phase 13B+ Recommendation

**Option 1: Proceed to Phase 13C (Automated Generation via Disabled-by-Default Hook)**
- Rationale: Workflow proven useful, governance maintained, data quality high
- Next: Implement disabled-by-default cron or manual trigger for routine artifact generation
- Timeline: 1-2 weeks

**Option 2: Proceed to Phase 13B (Dashboard/Static Viewer)**
- Rationale: Artifacts are human-readable and useful for research; dashboard could improve discoverability
- Next: Build static HTML disease map browser or embed in existing dashboard
- Timeline: 2-3 weeks

**Option 3: Combined Phase 13B+13C (Dashboard + Automated Generation)**
- Rationale: Maximize utility while maintaining governance isolation
- Next: Implement both dashboard viewer and disabled-by-default cron, wire together
- Timeline: 3-4 weeks

**Default Recommendation:** Start with Phase 13C (automated generation), followed by optional Phase 13B (dashboard) if user feedback is positive.

### Next Steps

1. User decision: Phase 13B (dashboard), Phase 13C (automation), or both?
2. Once decision made: implement chosen phase with same governance boundaries
3. Maintain 323-test suite as regression suite during future phases
4. Document final Phase 13B/C spec when ready

**Status:** `READY_FOR_PHASE_13B_DECISION`
